Viviane Quirke

Oestrogen and Time

Dr Viviane Quirke is Senior Lecturer in Modern History and the History of Biomedicine at Oxford Brookes University. She has written extensively about the history of drugs and the pharmaceutical industry in Britain, France and the US. She is currently deputy editor of the journal Ambix and a member of the Council of the Society for the history of Alchemy and Chemistry. 

Select bibliography:

Books: 

1. Collaboration in the Pharmaceutical Industry: changing relationships in Britain and in France, ca 1935-1965 (London/New York: Routledge, 2008).

Edited Collections:

Perspectives on twentieth-century Pharmaceuticals, edited collection with Judy Slinn (Oxford: Peter Lang, 2010).

Special Issues:

1. V. Quirke and P. Reed (eds), ‘Chemistry, consultants, and companies, c. 1850-2000’, Ambix (August 2020).
2. V. Quirke (ed), ‘Pharmaceutical styles of thinking and doing: French and British spheres of influence in the nineteenth and early-twentieth centuries’, Pharmacy in History, 52 (2010).
3. V. Quirke and J.-P. Gaudillière (eds), ‘The Era of Biomedicine: science, medicine and health in Britain and France, ca 1945-65’, Medical History, 52 (2008).

Articles:

1. ‘Chemistry, consultants, and companies, c. 1850-2000: an Introduction’, V. Quirke and P. Reed, in ‘Chemistry, consultants, and companies, c. 1850-2000’, special issue of Ambix (August 2020).
2. ‘From tamoxifen to SERMs: Imperial Chemical Industries and Craig Jordan, 1970s-2000’, in ‘The changing role of consultants in industry, 1850-2000’, eds. V. Quirke and P. Reed, special issue of Ambix (August 2020).
3. ‘Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation’, Frontiers in Pharmacology (12 Sept. 2017): 1663-9812 (DOI: 10.3389/fphar.2017.00620).
4. V. Quirke, ‘Pharmaceutical Innovation in the Public and Private Spheres,’ in P. Weindling (ed), Healthcare in Private and Public from the Early Modern Period to 2000 (Routledge, 2014), pp. 160-193.
5. ‘Targeting the American Market for Medicines, ca 1950s-1970s: ICI and Rhône-Poulenc compared,’ Bulletin of the History of Medicine 88 (2014): 654-696. (PMCID: PMC4335572).
6. ‘Thalidomide, Drug Safety Regulation and the British Pharmaceutical Industry: 
   the case of Imperial Chemical Industries’, in J.-P. Gaudillière and V. Hess (eds), Ways of Regulating Drugs in the 19^thand 20^th centuries (Basingstoke: Palgrave Macmillan, 2013), pp. 151-180.
7. ‘Foreign influences, national styles, and the creation of a modern pharmaceutical industry in Britain and France’, in V. Quirke (ed), ‘Pharmaceutical styles of thinking and doing: French and British spheres of influence in the nineteenth and early-twentieth centuries’, special issue, Pharmacy in History, 52 (2010): 134-47.